Models of neuroendocrine prostate cancer

Endocrine-Related Cancer

Volumn 22, Issue 1, 2015, Pages R33-R49

  Berman Booty, Lisa D ^a,b,c   Knudsen, Karen E ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cancer; Castration resistant prostate; Genetically engineered mice; Neuroendocrine prostate; Xenograft tumors

Indexed keywords

ANIMAL MODEL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MODEL; CARCINOGENESIS; CLINICAL FEATURE; DRUG TREATMENT FAILURE; GENETIC MANIPULATION; GENETICALLY ENGINEERED MOUSE STRAIN; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATIC ACINAR ADENOCARCINOMA; REVIEW; SMALL CELL CARCINOMA; SMALL CELL NEUROENDOCRINE CARCINOMA; TUMOR XENOGRAFT; ANIMAL; CARCINOMA; DISEASE MODEL; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; XENOGRAFT;

ANIMALS; CARCINOMA, NEUROENDOCRINE; DISEASE MODELS, ANIMAL; HETEROGRAFTS; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS;

EID: 84923560698     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0393     Document Type: Review

References (69)

1. Agemy L, Harmelin A, Waks T, Leibovitch I, Rabin T, Pfeffer MR & Eshhar Z 2008 Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts. Prostate 68 530-539. (doi:10.1002/pros. 20702)
2. Ahuja D, Saenz-Robles MT & Pipas JM 2005 SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 24 7729-7745. (doi:10.1038/sj.onc.1209046)
3. Ali SH & DeCaprio JA 2001 Cellular transformation by SV40 large T antigen: interaction with host proteins. Seminars in Cancer Biology 11 15-23. (doi:10.1006/scbi.2000.0342)
4. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM & Maity SN 2011 Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 71 846-856. (doi:10.1002/pros.21301)
5. Becher OJ & Holland EC 2006 Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Research 66 3355-3358 (discussion 3358-3359). (doi:10.1158/0008-5472.CAN-05-3827)
6. Beltran H 2014 The N-myc oncogene: maximizing its targets, regulation, and therapeutic potential. Molecular Cancer Research 12 815-822. (doi:10.1158/1541-7786.MCR-13-0536)
7. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al. 2011 Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discovery 1 487-495. (doi:10.1158/2159-8290.CD-11-0130)
8. Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G, Huang J, True L, Gleave ME, Soule H et al. 2014 Aggressive variants of castration-resistant prostate cancer. Clinical Cancer Research 20 2846-2850. (doi:10.1158/1078-0432.CCR-13-3309)
9. Berman-Booty LD, Thomas-Ahner JM, Bolon B, Oglesbee MJ, Clinton SK, Kulp SK, Chen CS & Perle KM 2014 Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice. Toxicologic Pathology [in press]. (doi:10.1177/019262331453135)
10. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, Cunha GR & Balmain A 2008 Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. American Journal of Pathology 172 236-246. (doi:10.2353/ajpath.2008.070602)
11. Clegg N, Ferguson C, True LD, Arnold H, Moorman A, Quinn JE, Vessella RL & Nelson PS 2003 Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate 55 55-64. (doi:10.1002/pros.10217)
12. Deng X, Elzey BD, Poulson JM, Morrison WB, Ko SC, Hahn NM, Ratliff TL & Hu CD 2011 Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients. American Journal of Cancer Research 1 834-844.
13. Duan W, Gabril MY, Moussa M, Chan FL, Sakai H, Fong G & Xuan JW 2005 Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model. Oncogene 24 1510-1524. (doi:10.1038/sj.onc.1208229)
14. Eble JN, Sauter G, Epstein JI & Sesterhenn IA (Eds) 2004 In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press.
15. Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, Robinson BD, Troncoso P & Rubin MA 2014 Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. American Journal of Surgical Pathology 38 756-767. (doi:10.1097/PAS.0000000000000208)
16. Ferlay J, Shin HR, Bray F, Forman D, Mathers C & Parkin DM 2010 Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 127 2893-2917. (doi:10.1002/ijc.25516)
17. Fine SW 2012 Variants and unusual patterns of prostate cancer: clinicopathologic and differential diagnostic considerations. Advances in Anatomic Pathology 19 204-216. (doi:10.1097/PAP.0b013e31825c6b92)
18. Gabril MY, Onita T, Ji PG, Sakai H, Chan FL, Koropatnick J, Chin JL, Moussa M & Xuan JW 2002 Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model. Gene Therapy 9 1589-1599. (doi:10.1038/sj.gt.3301895)
19. Gabril MY, Duan W, Wu G, Moussa M, Izawa JI, Panchal CJ, Sakai H & Xuan JW 2005 A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies. Molecular Therapy 11 348-362. (doi:10.1016/j.ymthe.2004.12.005)
20. Garabedian EM, Humphrey PA & Gordon JI 1998 A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. PNAS 95 15382-15387. (doi:10.1073/pnas.95.26.15382)
21. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM & Greenberg NM 1996 Metastatic prostate cancer in a transgenic mouse. Cancer Research 56 4096-4102.
22. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ & Greenberg NM 1997 Androgen-independent prostate cancer progression in the TRAMP model. Cancer Research 57 4687-4691.
23. Gingrich JR, Barrios RJ, Foster BA & Greenberg NM 1999 Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer and Prostatic Diseases 2 70-75. (doi:10.1038/sj.pcan. 4500296)
24. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ & Rosen JM 1995 Prostate cancer in a transgenic mouse. PNAS 92 3439-3443. (doi:10.1073/pnas.92.8.3439)
25. van Haaften-Day C, Raghavan D, Russell P, Wills EJ, Gregory P, Tilley W & Horsfall DJ 1987 Xenografted small cell undifferentiated cancer of prostate: possible common origin with prostatic adenocarcinoma. Prostate 11 271-279. (doi:10.1002/pros.2990110307)
26. Helpap B & Kollermann J 1999 Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Archiv 434 385-391. (doi:10.1007/s004280050357)
27. Helpap B, Kollermann J & Oehler U 1999 Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urologia Internationalis 62 133-138. (doi:10.1159/000030376)
28. Hill R, Song Y, Cardiff RD & Van Dyke T 2005 Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. Cancer Research 65 10243-10254. (doi:10.1158/0008-5472.CAN-05-1579)
29. Hu Y, Ippolito JE, Garabedian EM, Humphrey PA & Gordon JI 2002 Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice. Journal of Biological Chemistry 277 44462-44474. (doi:10.1074/jbc.M205784200)
30. Humphrey PA 2004 Gleason grading and prognostic factors in carcinoma of the prostate. Modern Pathology 17 292-306. (doi:10.1038/modpathol.3800054)
31. Humphrey PA 2012 Histological variants of prostatic carcinoma and their significance. Histopathology 60 59-74. (doi:10.1111/j.1365-2559.2011.04039.x)
32. Huss WJ, Gregory CW & Smith GJ 2004 Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence. Prostate 60 91-97. (doi:10.1002/pros.20032)
33. Irshad S & Abate-Shen C 2013 Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Reviews 32 109-122. (doi:10.1007/s10555-012-9409-1)
34. Jelbart ME, Russell PJ, Fullerton M, Russell P, Funder J & Raghavan D 1988 Ectopic hormone production by a prostatic small cell carcinoma xenograft line. Molecular and Cellular Endocrinology 55 167-172. (doi:10.1016/0303-7207(88)90131-1)
35. Jelbart ME, Russell PJ, Russell P, Wass J, Fullerton M, Wills EJ & Raghavan D 1989 Site-specific growth of the prostate xenograft line UCRU-PR-2. Prostate 14 163-175. (doi:10.1002/pros.2990140209)
36. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schroder FH & van Steenbrugge GJ 1999 Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. American Journal of Pathology 154 543-551. (doi:10.1016/S0002-9440(10)65300-X)
37. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van de Kwast TH, Schroder FH & van Steenbrugge GJ 2000 Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Research 60 741-748.
38. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schroder FH & van Steenbrugge GJ 2002 Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate 50 203-215. (doi:10.1002/pros.10049)
39. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA & Greenberg NM 2003 Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55 219-237. (doi:10.1002/pros.10215)
40. Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML & Matusik RJ 1998 Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Laboratory Investigation 78 319-333.
41. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ & Vasioukhin V 2004 Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 6 185-195. (doi:10.1016/j.ccr.2004.07.008)
42. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, Ichikawa T & Fuse H 2009 Neuroendocrine differentiation in the progression of prostate cancer. International Journal of Urology 16 37-44. (doi:10.1111/j.1442-2042.2008.02175.x)
43. Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N & Ittmann M 2001 Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. PNAS 98 11563-11568. (doi:10.1073/pnas.201167798)
44. Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmbhatt S, Mo F, Jong L et al. 2014 High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Research 74 1272-1283. (doi:10.1158/0008-5472.CAN-13-2921-T)
45. Littlepage LE, Sternlicht MD, Rougier N, Phillips J, Gallo E, Yu Y, Williams K, Brenot A, Gordon JI & Werb Z 2010 Matrix metallopro-teinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Research 70 2224-2234. (doi:10.1158/0008-5472.CAN-09-3515)
46. Marcus DM, Goodman M, Jani AB, Osunkoya AO & Rossi PJ 2012 A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer and Prostatic Diseases 15 283-288. (doi:10.1038/pcan.2012.4)
47. Maroulakou IG, Anver M, Garrett L & Green JE 1994 Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. PNAS 91 11236-11240. (doi:10.1073/pnas.91.23.11236)
48. Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB & Matusik RJ 2001 A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Research 61 2239-2249.
49. Masumori N, Tsuchiya K, Tu WH, Lee C, Kasper S, Tsukamoto T, Shappell SB & Matusik RJ 2004 An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. Journal of Urology 171 439-442. (doi:10.1097/01.ju.0000099826.63103.94)
50. Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir R et al. 2013 Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15 1-10.
51. Noordzij MA, van Weerden WM, de Ridder CM, van der Kwast TH, Schroder FH & van Steenbrugge GJ 1996 Neuroendocrine differentiation in human prostatic tumor models. American Journal of Pathology 149 859-871.
52. Pallas DC, Shahrik LK, Martin BL, Jaspers S, Miller TB, Brautigan DL & Roberts TM 1990 Polyoma small and middle T antigens and SV40 small T antigen form stable complexes with protein phosphatase 2A. Cell 60 167-176. (doi:10.1016/0092-8674(90)90726-U)
53. Pearse AG 1969 The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. Journal of Histochemistry and Cytochemistry 17 303-313. (doi:10.1177/17.5.303)
54. Perez-Stable C, Altman NH, Brown J, Harbison M, Cray C & Roos BA 1996 Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice. Laboratory Investigation 74 363-373.
55. Perez-Stable C, Altman NH, Mehta PP, Deftos LJ & Roos BA 1997 Prostate cancer progression, metastasis, and gene expression in transgenic mice. Cancer Research 57 900-906.
56. Pinthus JH, Waks T, Schindler DG, Harmelin A, Said JW, Belldegrun A, Ramon J & Eshhar Z 2000 WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma. Cancer Research 60 6563-6567.
57. Pipas JM 2009 SV40: cell transformation and tumorigenesis. Virology 384 294-303. (doi:10.1016/j.virol.2008.11.024)
58. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, Krajewski S, Mercola D, Carpenter PM, Bowtell D et al. 2010 Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 18 23-38. (doi:10.1016/j.ccr.2010.05.024)
59. Reiner T, de Las Pozas A, Parrondo R & Perez-Stable C 2007 Progression of prostate cancer from a subset of p63-positive basal epithelial cells in FG/Tag transgenic mice. Molecular Cancer Research 5 1171-1179. (doi:10.1158/1541-7786.MCR-07-0024)
60. Sausville EA & Burger AM 2006 Contributions of human tumor xenografts to anticancer drug development. Cancer Research 66 3351-3354 (discussion 3354). (doi:10.1158/0008-5472.CAN-05-3627)
61. Stein ME, Bernstein Z, Abacioglu U, Sengoz M, Miller RC, Meirovitz A, Zouhair A, Freixa SV, Poortmans PH, Ash R et al. 2008 Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications - a retrospective study of 30 patients from the rare cancer network. American Journal of Medical Sciences 336 478-488. (doi:10.1097/MAJ.0b013e3181731e58)
62. Suttie AW, Dinse GE, Nyska A, Moser GJ, Goldsworthy TL & Maronpot RR 2005 An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse. Toxicologic Pathology 33 386-397. (doi:10.1080/01926230590930272)
63. Tan HL, Sood A, Rahimi HA, Wang W, Gupta N, Hicks J, Mosier S, Gocke CD, Epstein JI, Netto GJ et al. 2014 Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clinical Cancer Research 20 890-903. (doi:10.1158/1078-0432.CCR-13-1982)
64. Tani Y, Suttie A, Flake GP, Nyska A & Maronpot RR 2005 Epithelial-stromal tumor of the seminal vesicles in the transgenic adenocarcinoma mouse prostate model. Veterinary Pathology 42 306-314. (doi:10.1354/vp.42-3-306)
65. True LD, Buhler K, Quinn J, Williams E, Nelson PS, Clegg N, Macoska JA, Norwood T, Liu A, Ellis W et al. 2002 A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. American Journal of Pathology 161 705-715. (doi:10.1016/S0002-9440(10)64226-5)
66. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM et al. 2012 Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clinical Cancer Research 18 666-677. (doi:10.1158/1078-0432.CCR-11-1867)
67. Wang W & Epstein JI 2008 Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. American Journal of Surgical Pathology 32 65-71. (doi:10.1097/PAS.0b013e318058a96b)
68. Yan Y, Sheppard PC, Kasper S, Lin L, Hoare S, Kapoor A, Dodd JG, Duckworth ML & Matusik RJ 1997 Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Prostate 32 129-139. (doi:10.1002/(SICI)1097-0045(19970701)32:2<129::AID-PROS8>3.0.CO;2-H)
69. Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, Roy-Burman P & Nikitin AY 2006 Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Research 66 7889-7898. (doi:10.1158/0008-5472.CAN-06-0486)